![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TMEM156 |
Gene summary for TMEM156 |
![]() |
Gene information | Species | Human | Gene symbol | TMEM156 | Gene ID | 80008 |
Gene name | transmembrane protein 156 | |
Gene Alias | TMEM156 | |
Cytomap | 4p14 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8N614 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80008 | TMEM156 | HCC1_Meng | Human | Liver | HCC | 2.21e-05 | -2.98e-02 | 0.0246 |
80008 | TMEM156 | cirrhotic2 | Human | Liver | Cirrhotic | 1.02e-04 | 1.60e-01 | 0.0201 |
80008 | TMEM156 | HCC2 | Human | Liver | HCC | 5.57e-04 | 1.03e+00 | 0.5341 |
80008 | TMEM156 | HCC5 | Human | Liver | HCC | 1.05e-03 | 1.95e+00 | 0.4932 |
80008 | TMEM156 | S027 | Human | Liver | HCC | 2.68e-08 | 7.56e-01 | 0.2446 |
80008 | TMEM156 | S028 | Human | Liver | HCC | 2.81e-06 | 4.17e-01 | 0.2503 |
80008 | TMEM156 | S029 | Human | Liver | HCC | 2.58e-11 | 6.69e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM156 | SNV | Missense_Mutation | c.677N>G | p.Phe226Cys | p.F226C | Q8N614 | protein_coding | deleterious(0) | possibly_damaging(0.794) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
TMEM156 | SNV | Missense_Mutation | c.185N>G | p.Gln62Arg | p.Q62R | Q8N614 | protein_coding | tolerated(0.07) | benign(0.022) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TMEM156 | SNV | Missense_Mutation | novel | c.402T>G | p.Phe134Leu | p.F134L | Q8N614 | protein_coding | tolerated(0.23) | benign(0.026) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TMEM156 | SNV | Missense_Mutation | novel | c.639N>T | p.Lys213Asn | p.K213N | Q8N614 | protein_coding | deleterious(0) | possibly_damaging(0.747) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TMEM156 | SNV | Missense_Mutation | c.487N>C | p.Asn163His | p.N163H | Q8N614 | protein_coding | tolerated(0.29) | benign(0.443) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
TMEM156 | SNV | Missense_Mutation | c.748N>A | p.Asp250Asn | p.D250N | Q8N614 | protein_coding | tolerated(0.23) | benign(0.009) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
TMEM156 | SNV | Missense_Mutation | novel | c.98N>C | p.Leu33Ser | p.L33S | Q8N614 | protein_coding | deleterious(0.02) | probably_damaging(0.936) | TCGA-EC-A1QX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD |
TMEM156 | SNV | Missense_Mutation | rs746613174 | c.539N>T | p.Ser180Leu | p.S180L | Q8N614 | protein_coding | tolerated(0.21) | benign(0.423) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TMEM156 | SNV | Missense_Mutation | novel | c.349N>G | p.Thr117Ala | p.T117A | Q8N614 | protein_coding | tolerated(0.19) | possibly_damaging(0.788) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM156 | SNV | Missense_Mutation | novel | c.505N>G | p.Thr169Ala | p.T169A | Q8N614 | protein_coding | tolerated(1) | benign(0) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |